Most Clicked StoriesMore >


Teva to acquire Allergan's generic business unit

BIO SmartBrief | Jul 27, 2015

Teva Pharmaceutical Industries will acquire Allergan's generic business unit for about $40.5 billion. The acquisition will strengthen Teva's presence in the generic-drugs market and help with cost reductions. Teva will drop its bid for Mylan, CEO Erez Vigodman said. The Wall Street Journal (tiered subscription model) (07/27)


Novartis transfers experimental drugs to British startup

BIO SmartBrief | Jul 30, 2015

Naurex to be purchased by Allergan

BIO SmartBrief | Jul 27, 2015

Merck to acquire cCAM Biotherapeutics

BIO SmartBrief | Jul 29, 2015

Report predicts 2020 drug trends

BIO SmartBrief | Jul 29, 2015

Sanofi unit to purchase AstraZeneca's thyroid cancer drug

BIO SmartBrief | Jul 28, 2015

Boehringer to sell generics business to Hikma Pharmaceuticals

BIO SmartBrief | Jul 29, 2015

Cancer drugs from Bristol-Myers, Kyowa Hakko Kirin to be combined in trial

BIO SmartBrief | Jul 31, 2015

Novartis' skin cancer drug gets FDA nod

BIO SmartBrief | Jul 27, 2015

Juno Therapeutics' application for leukemia drug approved by FDA

BIO SmartBrief | Jul 31, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the 2015 BIO Investor Forum!

BIO SmartBrief | Jul 31, 2015

Savings on environmental waste disposal services

BIO SmartBrief | Jul 31, 2015

Registration is open for the 2015 BIO Investor Forum!

BIO SmartBrief | Jul 30, 2015

Faster & better connections with quality R&D vendors

BIO SmartBrief | Jul 30, 2015

Registration is open for the 2015 BIO Latin America Conference!

BIO SmartBrief | Jul 29, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more